~ Here are a few recent 2013 findings on cannabinoids modulating other systems in our bodies: the roundup links to recent PubMed articles on the central nervous, circulatory, dopamine, integumentary (skin), lymphatic, and urinary systems.
I. Urinary System and CS
“Cannabinoids are reported to reduce sensory activity of isolated tissues, cause antihyperalgesia in animal studies of bladder inflammation, affect urodynamic parameters reflecting sensory functions in animal models, and appear to have effects on storage symptoms in humans.”
Cannabinoids and the endocannabinoid system in lower urinary tract function and dysfunction.
Neurourol Urodyn. 2013 Sep 23. doi: 10.1002/nau.22442. [Epub ahead of print]
PMID: 24285567 [PubMed - as supplied by publisher]
II. Integumentary System / Skin and CS
“Overall, these findings demonstrate that AEA [anandamide] induces cytotoxicity against human melanoma cells in the micromolar range of concentrations through a complex mechanism, which involves COX-2 and LOX-derived product synthesis and CB1 activation.”
Anticancer activity of anandamide in human cutaneous melanoma cells.
Adinolfi B, Romanini A, Vanni A, Martinotti E, Chicca A, Fogli S, Nieri P.
Eur J Pharmacol. 2013 Oct 15;718(1-3):154-9. doi: 10.1016/j.ejphar.2013.08.039. Epub 2013 Sep 13.
PMID: 24041928 [PubMed - in process]
III. Nervous System and CS
“This review will provide the reader with the foundational basic and clinical science linking the endocannabinoid system and the phytocannabinoids with their potentially therapeutic role in the management of chronic pain.”
The endocannabinoid system, cannabinoids and pain.
Fine PG, Rosenfeld MJ.
Rambam Maimonides Med J. 2013 Oct 29;4(4):e0022. doi: 10.5041/RMMJ.10129.
PMID: 24228165 [PubMed] Free PMC Article
IV. Central Nervous System / Autism and CS
“Our data indicate CB2 receptor as potential therapeutic target for the pharmacological management of the autism care.”
Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders.
Siniscalco D, Sapone A, Giordano C, Cirillo A, de Magistris L, Rossi F, Fasano A, Bradstreet JJ, Maione S, Antonucci N.
J Autism Dev Disord. 2013 Nov;43(11):2686-95. doi: 10.1007/s10803-013-1824-9.
PMID: 23585028 [PubMed - in process]
V. Circulatory and Lymphatic Systems / Bone Marrow and CS
“CBD may therefore recruit MSCs [mesenchymal stem cells] to sites of calcifying tissue regeneration and subsequently support bone regeneration via an osteoanabolic action on MSCs.”
Increase of mesenchymal stem cell migration by Cannabidiol via activation of p42/44 MAPK.
Schmuhl E, Ramer R, Salamon A, Peters K, Hinz B.
Biochem Pharmacol. 2013 Dec 1. pii: S0006-2952(13)00747-8. doi: 10.1016/j.bcp.2013.11.016. [Epub ahead of print]
PMID: 24304686 [PubMed - as supplied by publisher]
VI. Circulatory System and CS
“Cannabinoids also modulate the actions of vasoactive compounds including acetylcholine [nicotinic], methoxamine, angiotensin II and U46619 (thromboxane mimetic).”
Vascular targets for cannabinoids: animal and human studies.
Stanley C, O'Sullivan SE.
Br J Pharmacol. 2013 Dec 16. doi: 10.1111/bph.12560. [Epub ahead of print]
PMID: 24329566 [PubMed - as supplied by publisher]
VII. Dopamine System and CS
“Cannabinoids also increase dopamine release within the mesolimbic system, a neural pathway generally implicated in timing behavior.”
Cannabinoid receptor activation shifts temporally engendered patterns of dopamine release.
Oleson EB, Cachope R, Fitoussi A, Tsutsui K, Wu S, Gallegos JA, Cheer JF.
Neuropsychopharmacology. 2013 Dec 18. doi: 10.1038/npp.2013.340. [Epub ahead of print]
PMID: 24345819 [PubMed - as supplied by publisher]